Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

KMDABearishCorporate Developmentsnews

High materiality7/10

Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook

Dec 8, 2025, 11:31 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The discontinuation of the trial suggests significant setback, causing immediate investor concern. Historical trends show stock declines follow failed clinical trials, like with Incyte in 2019.

AI summary

What happened, with direct paths to the underlying reporting

Kamada discontinues Phase 3 trial for inhaled AAT due to limited efficacy. Shares down 5.51% following the trial discontinuation announcement. CEO emphasizes strong growth prospects despite trial outcome. Full-year 2025 revenue guidance remains between $178M to $182M. Kamada plans double-digit growth through commercial portfolio expansion.

Kamada discontinues Phase 3 trial for inhaled AAT due to limited efficacy.
Shares down 5.51% following the trial discontinuation announcement.
CEO emphasizes strong growth prospects despite trial outcome.
Full-year 2025 revenue guidance remains between $178M to $182M.
Kamada plans double-digit growth through commercial portfolio expansion.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.